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Editorial on the Research Topic
Purinergic Pharmacology
The purine nucleotides and nucleosides constitute important extracellular signaling molecules
acting as neurotransmitters and neuromodulators. Indeed, extracellular adenosine 5′-triphosphate
(ATP) and adenosine, tightly controlled by nucleotidases, ribokinases, deaminases, and
transporters, signal through a rich array of purinergic receptors. These receptors, which
emerged early in evolution, are among the most abundant in living organisms controlling many
physiological actions, thus becoming promising therapeutic targets in a wide range of pathological
conditions. Thus, while P1 receptors are selective for adenosine, a breakdown product of ATP,
P2 receptors are activated by purine nucleotides, as well as P2Y receptors being activated by
pyrimidine nucleotides. Interestingly, purinergic receptors, both G protein-coupled (i.e., P1 and
P2Y) and ligand-gated ion channel (i.e., P2X) receptors, are involved in many neuronal and
non-neuronal mechanisms, including pain, immune responses, exocrine and endocrine secretion,
platelet aggregation, endothelial-mediated vasodilatation and inflammation, among others.
Purinergic receptors are ubiquitously expressed throughout the body, thus compromising
the specificity of receptor subtype-selective drugs and increasing the possibility of side
effects upon pharmacological intervention. However, the extracellular levels of purines may
fluctuate enormously, thus distinct purinergic receptors responding differently to low and high
concentrations of endogenous purines are called into action while cells are exposed to multiple
purinergic signaling molecules. Therefore, the same cell usually concurrently expresses different
subtypes of P1 and P2 receptors, which allows the integration of purinergic transmission into
short- and long-term signaling events. Consequently, drug selectivity constitutes another important
pharmacological goal within the purinergic field. Indeed, the development of potent and selective
synthetic agonists and antagonists for purinergic receptors has been the subject of medicinal
chemistry research for decades. In addition, allosteric modulators of purinergic receptors have
been successfully developed. Interestingly, these compounds allow the manipulation of the
endogenous purinergic system in an event-responsive and temporally specific manner, thus
offering a unique therapeutic window when compared to orthosteric compounds. Finally, the
functioning of the purinergic system could be also manipulated by modulating the metabolism
and/or uptake of extracellular purine nucleotides and nucleosides. Overall, there is no doubt that
purinergic pharmacology is growing fast and becoming an attractive field for pharmacotherapeutic
development.
In this timely research topic, an overview of the purinergic pharmacology is provided through
61 articles written by 439 authors. This successful compilation contains 15 reviews, 5 mini
reviews, 3 hypothesis and theory papers, 1 perspective, and 37 original research papers. The
reviews summarize the currently available knowledge on the role of purinergic signaling, focusing
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on the pathophysiology and its therapeutic potential (Burnstock),
for example, in mast cell degranulation and its most relevant
disease, asthma (Gao and Jacobson), pulmonary arterial
hypertension (Alencar et al.), amyotrophic lateral sclerosis
(Sebastião et al.), neurodevelopmental disorders (Fumagalli
et al.), epilepsy (Alves et al.), neurological diseases with motor
symptoms (Oliveira-Giacomelli et al.), motivational dysfunction
and depression (López-Cruz et al.), and inflammatory diseases
(Savio et al. ), In addition, some of the reviews provide more
mechanistic opinions, for instance on purinergic transmission
in psychostimulant addiction (Ballesteros-Yáñez et al.), carotid
body physiology (Conde et al.), and platelet heterogeneity
(Koupenova and Ravid). Also, some hints about the molecular
mechanism of ligand binding and activation by adenosine
(Carpenter and Lebon) and ATP (Di Virgilio et al.) receptors is
provided. Finally, the impact of adenosine transport in purinergic
signaling is also reviewed (Pastor-Anglada and Pérez-Torras).
Subsequently, five minireviews highlight diverse aspects of
purinergic signaling. For instance, the role of adenosine and
its receptors in T cell development in the thymus (Köröskényi
et al.) and the regulation of the activity of immune cells
and enteric nervous system (Dal Ben et al.). Thus, the
most promising purine-based strategies are summarized for
the treatment of inflammation-related disorders, including
the recent development of nanobodies against key targets of
purinergic system (Menzel et al.). Next, the current knowledge
on the pathophysiological involvement of purinergic receptors
in white and brown adipocytes and their potential use in
metabolic disorders is reviewed (Tozzi and Novak). Also, the
recent emerging data involving the ATP-gated P2X7 ion channel
as a potential drug target for central nervous system disorders
including neuropsychiatric conditions (Bhattacharya).
In the section “Hypothesis and Theory” the molecular
determinants of small-molecule ligand (i.e., BzATP and
ivermectin) binding at P2X receptors is reviewed grounded in
structure-based docking studies (Pasqualetto et al.). Next, the
interplay of adenosine receptors with muscarinic acetylcholine
and neurotrophin receptors in the mammalian neuromuscular
junction controlling synapse elimination and neurotransmission
release is considered (Tomàs et al.). Also, the formation of
adenosine A2A and dopamine D2 receptor heterotetramers
and adenylate cyclase type 5 complexes in striatopallidal
neurons are postulated as an integrative device tuning adenosine
and dopamine signaling and therefore behavioral effects of
adenosine/dopamine-based ligands (Ferré et al.). Finally,
a perspective paper discusses the current limitations and
highlights future research directions to achieve adenosine
receptor-mediated cardioprotection (Lasley).
The research topic contains a series of original research
papers covering important aspects of purinergic pharmacology.
Thus, several papers focus on the role of adenosine receptors
in cancer cells proliferation (Gessi et al.), morphologically
altered hippocampal neurons (Pinheiro et al.), hippocampal
slices subjected to oxygen and glucose deprivation (Fusco
et al.), instrumental animal learning (Li et al.), and rodent
models of movement disorders (Núñez et al.). Indeed, the
interest of targeting adenosine receptors is also shown by the
design of a non-imaging high throughput approach to screen
drugs in native receptors (Arruda et al.) and their detection
in human brain using positron emission tomography (PET)
ligands (Mishina et al.). In addition, some molecular clues
about adenosine receptor function are also given, for instance,
the formation of transcellular trimeric complexes involving
CD26, adenosine deaminase and adenosine A2A receptor (A2AR)
(Moreno et al.), the A2AR-mediated control of glutamatergic
synaptic plasticity in prefrontal cortex interneurons (Kerkhofs
et al.) and the adenosine A2B receptor (A2BR)-mediated control
of epithelial-mesenchymal transition by tuning the cAMP/PKA
and MAPK/ERK balance (Giacomelli et al.). Also, it is speculated
whether A2AR may be useful to sustain contractility in failing
human hearts and upon ischemia and reperfusion (Boknik
et al.). Finally, the role of caffeine in controlling glutamatergic
synaptic transmission in human cortical neurons (Kerkhofs et al.)
and its adverse effects in an Alzheimer’s disease animal model
(Baeta-Corral et al.) are investigated.
The role of the purinergic system in microglia and
astrocytic function both in vitro and in vivo is studied in
glaucoma (Rodrigues-Neves et al.), prostaglandin E2 signaling
(Paniagua-Herranz et al.), extracellular vesicle-based cell
communication (Drago et al.), cell migration (Adzic and
Nedeljkovic) and proliferation (Quintas et al.). Similarly, the
impact on T cells (Shinohara and Tsukimoto; Soslow et al.)
and cytokine-induced killer cell function (Horenstein et al.) is
also explored. Interestingly, extracellular signaling by guanine-
based purines was explored in cultured cells (Pietrangelo et al.;
Zuccarini et al.) and in rodent models of movement disorders
(Massari et al.).
The extracellular ATP/adenosine ratio is a key element
for immune responses, including post-inflammatory ileitis, as
described in this research topic (Vieira et al.). Thus, the
tissue-nonspecific alkaline phosphatase enzyme and Pannexin-
1 channel seem to play an important physiological role
regulating the levels of extracellular ATP (Sebastián-Serrano
et al.), which ultimately will activate cell surface P2XRs and
P2YRs. In addition, it seem that ATP release, at least in the
suprachiasmatic nucleus, is under the control of these two
kinds of purinergic receptors (Svobodova et al.). Interestingly,
P2XRs are allosterically modulated by trace metals (i.e., zinc)
and other drugs (i.e., ivermectin) (Latapiat et al.), which
also can form heterotrimeric P2X4/P2X7 receptors (Schneider
et al.). Importantly, P2X7R is up-regulated and promotes a
fibrogenic phenotype in systemic sclerosis (SSc) fibroblasts,
thus becoming a potential therapeutic target in SSc patients
(Gentile et al.). Conversely, P2YR expression seems to play a
key role in eye physiology. Thus, changes in the P2Y2/P2Y1
expression ratio correlates well with an increment in the
intraocular pressure in an animal model of glaucoma (Fonseca
et al.). Also, P2Y12R blockade facilitate the clearance of
lysosomal waste in retinal pigmented epithelial cells, which
is relevant for age-related macular degeneration management
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(Lu et al.). Furthermore, a clinical study revealed that P2Y12R
blockade does not contribute to risk of osteoporotic fractures in
stroke patients, a common adverse effect of transient ischemic
attack treatment (Jørgensen et al.). In a separate context, the
P2Y6R regulates chemokine (i.e., CXCL10) secretion in mouse
intestinal epithelia cells, thus regulating gut homeostasis (Salem
et al.).
As a neurotransmitter, ATP is stored in secretory vesicles,
a process mediated by the vesicular nucleotide transporter
(VNUT). In this research topic it is demonstrated that cerebellar
granule cells express functional VNUT and that may be
implicated in the initial stages of granule cell development
(Menéndez-Méndez et al.). Finally, the issue also reports the
generation and characterization of a valuable, new tool to study
ectonucleotidase nucleoside triphosphate diphosphohydrolase-8
(NTPDase8) (Pelletier et al.) and the characterization of uridine
adenosine tetraphosphate’s (Up4A) physiological role in in vivo
heart failure model, i.e., swine aortic banding (Zhou et al.).
Overall, this research topic provides new insights into the
vast physiological roles of purinergic signaling and its structural
and mechanistic basis. This field offers enormous possibilities for
translation of basic science into novel treatments for chronic and
acute diseases, while at the same time it presents a challenge to
achieve selectivity of drug action.
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